Results 61 to 70 of about 6,092,576 (159)

Characteristics of 8 patients former finasteride users, finasteride self-reported side effects and sexual function information.

, 2014
aComparison between present and pre-finasteride use ASEX scores, 2-sided P value was evaluated by the Mann-Whitney U-test.bTestosterone supplementation post-finasteride was terminated over 1 year before present study entry.
Emanuele Belgrano (588084), Sabina Cauci (561270), Giorgio Mazzon (588083), Carla Di Loreto (20344), Francesco La Marra (588082), Carlo Trombetta (588085)   +5 more
core   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, Volume 5, Issue 2, Page 385-393, June 2026.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

Treatment of Tourette's syndrome with finasteride

, 2007
The marked male predominance of Tourette’s syndrome suggests that androgens may play a key role in the pathophysiology of this disorder. Accordingly, androgen receptor antagonists, such as flutamide, significantly attenuate Tourette’s syndrome symptoms ...
MURONI A, BORTOLATO M, MARROSU, FRANCESCO, . NO ABSTRACT A.V.A.I.L.A.B.L.E. PMID PUBMED INDEXED FOR MEDLINE, MARROSU F   +4 more
core   +1 more source

Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System

Journal of Dermatological Treatment
Background Oral finasteride 1 milligram (1 mg) daily—which is a 5-alpha reductase inhibitor (5-ARI) approved by the Food and Drug Administration (FDA) for androgenetic alopecia—is linked to sexual adverse events (AEs). However, it remains unclear whether
Aditya K. Gupta, Mesbah Talukder, Greg Williams, Mary A. Bamimore   +3 more
doaj   +1 more source

Skin Boosters: 2026 Updated

Journal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.
ABSTRACT Skin boosters are increasingly used to improve dermal quality through injectable and device‐assisted approaches; however, definitions and clinical evidence remain heterogeneous. Aims To provide an updated overview and propose a practical classification of skin boosters, including mechanisms, delivery methods, clinical outcomes, and limitations.
Kyu‐ho Yi, Hyunggyu Kang, Jong Keun Song, Olena Sydorchuk, Jeremy B. Green, Hugues Cartier, Roya Zarmehr Zamin, Benjamin Ascher   +7 more
wiley   +1 more source

Post-Finasteride Syndrome: About 2 Cases and Review of the Literature

Andrology-Open Access, 2016
Introduction: Finasteride is widely used in the treatment of benign prostatic hyperplasia and androgenetic alopecia. Persistent sexual adverse events in patients that withdraw the drug was poorly studied. Materials and methods: case report study of two clinical cases of post-finasteride syndrome.
Alejandro Silva Garreton, Gaston Rey Valzacchi, Omar Layus   +2 more
openaire   +1 more source

A Scoping Review of Non‐Opioid Therapeutics for Opioid Withdrawal: Translational Relevance to Neonatal Opioid Withdrawal Syndrome (NOWS) Research

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT In the wake of the ongoing opioid epidemic, the incidence of neonatal opioid withdrawal syndrome (NOWS) has surged. While the short‐term effects of NOWS are well‐characterized, long‐term physiological and molecular consequences remain unclear.
Sara L. Mills‐Huffnagle, Oliver M. Lowden, Rhea E. Sullivan, Taryn E. McFadden, Jennifer E. Nyland   +4 more
wiley   +1 more source

An (Ir)reversible Affection of the Sexual Sphere: A Case Report

Journal of Psychosexual Health
Background: Finasteride, a 5α-reductase inhibitor (5αRI) for benign prostatic hyperplasia and androgenetic alopecia (AGA), has been linked to persistent multisystemic symptoms—most often sexual dysfunction—that may appear during or after use and persist ...
Sofia Mendes Cunha
doaj   +1 more source

Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease

Advanced Science, Volume 13, Issue 20, 9 April 2026.
This research identified cardiac amyloid pathology, neurotrophic factor depletion, and reduced myocardial nerve function in a transgenic model of cerebral amyloidosis (Tg2576), Aβ‐challenged cardiomyocytes, and in human AD heart tissue. These findings carry significant diagnostic and therapeutic implications, emphasizing the role of neuro‐signaling ...
Andrea Elia, Rebecca Parodi‐Rullan, Rafael Vazquez‐Torres, Ashley Carey, Huaqing Zhao, Sabzali Javadov, Silvia Fossati   +6 more
wiley   +1 more source

Research Progress on Platelet‐Rich Plasma (PRP) in the Treatment of Androgenetic Alopecia

Journal of Cosmetic Dermatology, Volume 25, Issue 4, April 2026.
ABSTRACT Background Androgenetic alopecia (AGA) is the most common cause of progressive hair loss, significantly affecting quality of life. Current therapies, such as minoxidil, finasteride, and hair transplantation, show variable efficacy and may be associated with adverse effects.
Zetian Zhong, Li Luo, Lixiang Zhao, Xupeng Yue, Yanxin Lu   +4 more
wiley   +1 more source